Features

In a planned succession,Julie Kim took the helm at Takeda as President and CEO with former President and CEO Christophe Weber stepping down following a 12-year tenure. The company faces…

FDA’s Emerging Technology Program, a collaborative program between the agency and industry, aims to facilitate bio/pharma companies’ adoption of new manufacturing technologies, including continuous manufacturing. Where do things stand?

GPL-1s for treating Type 2 diabetes and obesity have been a key growth driver for the bio/pharma industry as well as for CDMOs of injectables, but will the entry of oral GLP-1s and related drugs put a damper on growth prospects for injectables? What is the expected market penetration?

Delivering value beyond product and price is crucial for CDMOs and suppliers to gain a competitive edge with their bio/pharma customers, but are the buy and sell side aligned in what constitutes value? The latest DCAT Benchmarking & Research study provides key insights.

At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing

What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…

Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?

ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?

Lilly has been active on the M&A front with a series of biotech acquisitions totaling up to more than $20 billion in 2026 to date  What moves is the company making?

European policymakers reached a provisional agreement on the Critical Medicines Act, designed to strengthen the EU’s pharma manufacturing base. What is next?